ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2016 American Transplant Congress

    Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.

    C. Legendre,1 J. Campistol,2 T. Feldkamp,3 J. Wang,4 G. Remuzzi,5 L. Weekers,6 N. Sheerin.7

    1Université Paris Descartes & Hôpital Necker, Paris, France; 2Hospital Clinic, University of Barcelona, Barcelona, Spain; 3University Hospital Schleswig-Holstein, Kiel, Germany; 4Alexion Pharmaceuticals, Inc., Cheshire, CT; 5IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy; 6CHU de Liège, Liège, Belgium; 7Newcastle University, Newcastle upon Tyne, United Kingdom.

    Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes…
  • 2016 American Transplant Congress

    Factors Associated with Acute Rejections in Kidney Transplant Recipients: Time for HLA-DR Matching in Elderly Recipients?

    D. Khadzhynov, F. Halleck, L. Lehner, M. Duerrr, A. Kleinsteuber, D. Schmidt, K. Budde, O. Staeck.

    Nephrology, Charite Universitaetsmedizin, Berlin, Germany.

    Background. Within the Eurotransplant Senior Allocation Program (ESP) HLA-matching is neglected,potentially causing inferior outcomes. There is a lack of data analysing the long-term immunologic outcomes…
  • 2016 American Transplant Congress

    Significant Association of Vitamin-D Receptor (VDR) Gene Polymorphism and Incidence of De Novo DSA in Renal Transplantation.

    L. Das, K. Ide, Y. Tanaka, N. Tanimine, S. Verma, H. Ohdan.

    Department of Gastroenrological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.

    Objective-Renal Transplantation (RT) is the optimal choice forend stage renal disease. Despite all advances in the development ofeffective immunosuppressive regimens in renal transplantation one of…
  • 2016 American Transplant Congress

    The Live Donor Champion Program: A Novel Approach to Identying Live Kideny Donors.

    E. King, M. Bowring, K. Kumar, J. Garonzik Wang, D. Segev.

    Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.

    Background: The Live Donor Champion (LDC) program is a clinical program offered to kidney waitlist candidates at our high volume transplant center. The six-month program…
  • 2016 American Transplant Congress

    Implications of Subclinical Borderline Acute Cellular Rejection Detected in Protocol Biopsies on Graft Outcomes.

    Z. Zaky,1 C. Yu,1 N. Elfadawy,2 A. Chiesa-Vottero,1 L. Herlitz,1 S. Flechner,1 E. Poggio.1

    1Glickman Urological and Kidney institute, Cleveland Clinic, Cleveland, OH; 2Internal Medicine, Univ. Hospitals Case Medical Center, Cleveland, OH.

    Background: The effects of subclinical borderline acute cellular rejection (BACR-defined as I1T1 per Banff criteria) detected in protocol biopsies (Bx) on subsequent graft function and…
  • 2016 American Transplant Congress

    Removing Geographic and Financial Barriers for Directed Living Kidney Donations: Lessons from Kidney Paired Donation.

    M. Aeder,1 R. Leishman,2 D. Stewart.2

    1Univ Hosp Case Med Ctr, Cleveland, OH; 2UNOS, Richmond, VA.

    Living donor (LD) kidney (K) transplants (Tx), which peaked at 6647 in 2004 (42.5% of tx), decreased by 2014 to 5538 (32.4% of tx). Although…
  • 2016 American Transplant Congress

    ABO Incompatible Living Related Kidney Transplantation: Results of a Matched-Pair Analysis with ABO Compatible Living Donation.

    T. Vowinkel,1 H. Wolters,2 S. Reuter,3 T. Vogel,1 N. Senninger,1 B. Suwelack.3

    1Department of General and Visceral Surgery, University Hospital Muenster, Muenster, Germany; 2Department of General and Visceral Surgery, St. Josef's Hospital, Dortmund, Germany; 3Department of Internal Medicine D, University Hospital Muenster, Muenster, Germany.

    Background: Organ shortage has led to an increase in living related kidney transplantation of ABO compatible (ABOc) as well as ABO incompatible (ABOi) organs. Here…
  • 2016 American Transplant Congress

    Age and Education Level Are Predictors of Patient Preferences for Educational Formats in ESRD Patients Undergoing Transplant Education.

    K. Leick,1 J. Jones,1 S. Witte,2 L. Hunsicker,3 Z. Stewart.1

    1Dept of Surgery, University of Iowa, Iowa City, IA; 2Dept of Social Services, University of Iowa, Iowa City, IA; 3Dept of Internal Medicine, University of Iowa, Iowa City, IA.

    Background: Health literacy impacts hospitalizations and mortality. ESRD patients have reduced health literacy due to a high proportion of lower educational background and socioeconomic resources.…
  • 2016 American Transplant Congress

    Limited Efficacy of Bortezomib on Desensitization via Rapid Humoral Compensation in a Sensitized Rhesus Model.

    J. Kwun,1 C. Burghuber,1 N. Iwakoshi,2 A. Gibby,2 S. Knechtle.1

    1Surgery, Duke University, Durham; 2Surgery, Emory University, Atlanta.

    Sensitized patients comprise a significant proportion (30%) of candidates on the waiting list for transplantation. With recent evidence that the presence of donor-specific antibodies (DSA)…
  • 2016 American Transplant Congress

    Immunologic Basis for Immunocloaking.

    L. Brasile,1 K. Kizjakina,1 N. Henry,1 B. Stubenitsky.2

    1BREONICS Inc., Watervliet, NY; 2Plastic Surgery, University of Utrecht, Utrecht, Netherlands.

    A novel organ-specific immunomodifying therapy referred to as immunocloaking (IC) provides protection from early allograft rejection without immunosuppressive drugs. The IC binds to the surfaces…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 180
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences